Back to news

CELLYAN BIOTECHNOLOGY CO., LTD REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

Globe Newswire•16/11/2026•06:40 ET
1

Key Highlights

  • ➤Cellyan Biotechnology (HKPD) regained Nasdaq minimum bid price compliance.
  • ➤HKPD shares closed at least $1.00 for 14 consecutive business days.
  • ➤Nasdaq closed the compliance matter after notice on November 13, 2026.

Hong Kong, China, Nov. 16, 2026 (GLOBE NEWSWIRE) -- Cellyan Biotechnology Co., Ltd (Nasdaq: HKPD) (the “Company”), a leading provider of over-the-counter (“OTC”) pharmaceutical cross-border e-commerce supply chain services in Hong Kong, today announced that it received written notification from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) on November 13, 2026, confirming that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) for continued listing on the Nasdaq Capital Market.

As previously announced, on January 12, 2026, Nasdaq notified the Company that the closing bid price of the Company’s Class A ordinary shares had been below US$1.00 per share for 30 consecutive business days and that, as a result, the Company was not in compliance with the Minimum Bid Price Requirement. Nasdaq provided the Company with an initial compliance period of 180 calendar days, or until July 13, 2026, to regain compliance. To regain compliance, the Company was required to maintain a closing bid price of at least US$1.00 per share for a minimum of 10 consecutive business days during the compliance period. On July 14, 2026, the Company received written notice from Nasdaq granting an additional 180 calendar days, or until January 11, 2027, to regain compliance with the Minimum Bid Price Requirement.

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in